首页> 外文期刊>Arthritis and Rheumatism >Dexamethasone prodrug treatment prevents nephritis in lupus-prone (NZB × NZW)F1 mice without causing systemic side effects
【24h】

Dexamethasone prodrug treatment prevents nephritis in lupus-prone (NZB × NZW)F1 mice without causing systemic side effects

机译:地塞米松前药治疗可预防易患狼疮(NZB×NZW)F1小鼠的肾炎而不会引起全身性副作用

获取原文
获取原文并翻译 | 示例
           

摘要

Objective To evaluate the potentially improved therapeutic efficacy and safety of nephrotropic macromolecular prodrugs of glucocorticoids (GCs) for the treatment of lupus nephritis. Methods Lupus-prone female (NZB × NZW)F1 mice received monthly injections of N-(2-hydroxypropyl) methacrylamide copolymer-based dexamethasone prodrug (P-Dex) or daily injections of dexamethasone phosphate sodium (Dex; overall dose equivalent to that of P-Dex) for 2 months. During treatment, the mice were monitored for albuminuria, mean arterial pressure, and serum autoantibody levels. Nephritis, renal immune complex levels, and macrophage infiltration were evaluated histologically. Bone quality was analyzed using peripheral dual x-ray absorptiometry and micro-computed tomography. The in vivo distribution of P-Dex was investigated using optical imaging, immunohistochemistry, and fluorescence-activated cell sorting (FACS). The antiinflammatory effect of P-Dex was validated using lipopolysaccharide-activated human proximal tubule epithelial (HK-2) cells. Results Monthly P-Dex injections completely abolished albuminuria in the (NZB × NZW)F1 mice; this approach was significantly more efficacious than daily Dex treatment. P-Dex treatment did not reduce serum levels of anti-double-stranded DNA antibodies or renal immune complexes but did decrease macrophage infiltration, which is a marker of chronic inflammation. Immunohistochemical and FACS analyses revealed that P-Dex was primarily sequestered by proximal tubule epithelial cells, and that it could attenuate the inflammatory response in HK-2 cell culture. In contrast to Dex treatment, P-Dex treatment did not lead to any significant deterioration of bone quality or reduction in the level of total serum IgG. Conclusion Macromolecularization of GCs renders them nephrotropic. Protracted retention, subcellular processing, and activation of GC prodrugs by kidney cells would potentiate nephritis resolution, with a reduced risk of systemic toxicities.
机译:目的评估糖皮质激素(GCs)肾病性大分子前药治疗狼疮性肾炎的潜在疗效和安全性。方法易患狼疮的雌性(NZB×NZW)F1小鼠每月注射基于N-(2-羟丙基)甲基丙烯酰胺共聚物的地塞米松前药(P-Dex)或每日注射地塞米松磷酸钠(Dex;总剂量等于P-Dex)2个月。在治疗期间,监测小鼠的蛋白尿,平均动脉压和血清自身抗体水平。通过组织学评估肾炎,肾免疫复合物水平和巨噬细胞浸润。使用外围双X线骨密度仪和微型计算机断层扫描对骨质量进行分析。使用光学成像,免疫组织化学和荧光激活细胞分选(FACS)研究了P-Dex的体内分布。使用脂多糖激活的人近端肾小管上皮细胞(HK-2)验证了P-Dex的抗炎作用。结果每月注射P-Dex可完全消除(NZB×NZW)F1小鼠的蛋白尿;这种方法比每日Dex治疗有效得多。 P-Dex治疗并未降低抗双链DNA抗体或肾脏免疫复合物的血清水平,但确实减少了巨噬细胞浸润,这是慢性炎症的标志。免疫组织化学和FACS分析表明,P-Dex主要被近端小管上皮细胞隔离,并且它可以减弱HK-2细胞培养物中的炎症反应。与Dex治疗相比,P-Dex治疗不会导致骨骼质量明显下降或血清总IgG水平降低。结论GC的大分子化使其具有亲肾性。肾脏细胞长时间滞留,亚细胞加工和激活GC前药会增强肾炎的消退,降低全身毒性的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号